Company

Preaxa for investors

Preaxa is building the preparation and follow-up layer for outpatient care in India: every consultation starts from a patient-verified docket, and every treatment gets a recorded outcome.

The problem

Indian outpatient consultations are among the shortest recorded in published international comparisons — frequently just a few minutes. Most of those minutes go to history-taking from scratch. Reports are photographs on a phone. Once the patient leaves, nobody records whether the prescription worked. Chronic conditions get managed this way — diabetes alone affects over a hundred million Indian adults (ICMR-INDIAB, 2023), and a diabetes patient sees a doctor several times a year.

The product

The docket. An AI-guided intake interviews the patient before the appointment — unhurried, hypothesis-driven, in English or Hindi — reads their reports, and compiles a one-page, patient-approved summary the doctor absorbs in under a minute. The AI never diagnoses; it prepares. The doctor decides.

The follow-up loop. After the consultation, patient updates and new reports come through the platform instead of the doctor's personal WhatsApp. They sit against the treatment plan, they're on the record, and the doctor can charge for the work.

The EMR. Every docket, prescription, and follow-up lands in the patient's longitudinal record. The doctor does no data entry — the intake and the consultation produce the record as a side effect.

Why now

The models got good enough. A structured-output LLM can now run a disciplined, guardrailed clinical interview. Preaxa's intake runs on OpenAI, Google, or Anthropic models and is quality-gated by an automated eval harness.
ABDM/ABHA give India a national health-record system to read from and write to. UPI normalized paying digitally. The 2020 Telemedicine Practice Guidelines made remote consultation a defined, legal practice.
India's data-protection law (DPDP) is now concrete enough to build consent-first health infrastructure against.

Business model

A fixed platform fee on every consultation, charged to the patient on top of the doctor's own fee — the doctor keeps 100% of theirs, which is central to the doctor-first distribution motion. The second line is a chronic-care subscription bundling follow-ups and recall; the third is lab-order routing from the structured test orders doctors already write on the platform.

Distribution

Doctor-first: doctors are the customer and the patient-acquisition channel. Each doctor gets a public booking page and a clinic QR poster; their existing panel becomes the initial patient base at zero acquisition cost. The wedge is chronic, lab-driven specialties — endocrinology, cardiology, nephrology, gastroenterology — where the docket and the follow-up loop matter most and visits recur.

Moat

The record compounds: every episode adds to a patient history that exists nowhere else in this form. The doctor's practice data lives here. Ratings come only from completed consultations. Referrals between doctors on the platform bring in the next specialty.

Status

The platform is live end to end — AI intake with deterministic clinical guardrails, sealed dockets, slot booking and payments scaffolding, e-prescriptions with telemedicine-schedule enforcement, follow-up threads, billing and receipts, a doctor EMR seed, and an operations console. Intake quality is measured against a versioned eval baseline. The company is pre-revenue and onboarding its first wedge-specialty doctors.

Contact

For the current deck and a product walkthrough: investors@preaxa.com.